Two new drugs debut on the PBS

Two drugs have been subsidised on the PBS for the first time from 1 August, while some big names saw expansions to their indications and others faced the entry of the first biosimilar competition.

AbbVie's Vyalev has been listed for the treatment of advanced idiopathic Parkinson's in people with severe motor fluctuations despite optimised alternative pharmacological treatment.

It received a PBAC recommendation in the November 2024 meeting, after being knocked back in May that year.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here